Recent studies indicated a substantial role of BLyS (BAFF, TNFSF13B) in the pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in humans and in animal models. This study was conducted to screen for polymorphisms of human BLYS, and to examine whether they are involved in the genetic susceptibility to human SLE and RA. A systematic polymorphism screening was performed in the coding region, 5 0 and 3 0 untranslated regions, and promoter region of human BLYS. Association of the detected polymorphisms with SLE and RA was analyzed in 221 Japanese patients with RA, 156 with SLE, and 227 healthy individuals, using the case-control approach. Four single nucleotide polymorphisms (SNPs) in the promoter, one SNP in intron 1, and one rare nonsynonymous substitution (Ala105Thr) in the coding region were detected. The BLYS SNPs were found to form three common haplotypes. Significant association with the susceptibility to SLE or RA was not observed. However, a tendency for the increase of À871T/T genotype was observed in SLE patients with anti-Sm antibody (P ¼ 0.082). BLYS mRNA level was significantly elevated in the monocytes from individuals carrying À871T (P ¼ 0.010). In addition, although statistically not significant, 105Thr allele was slightly increased in patients with RA compared with controls (P ¼ 0.058). Characterizing the functional and clinical significance of these new SNPs requires further study.
Introduction
B lymphocyte stimulator (BLyS, also known as BAFF, TALL-1, zTNF4, TNFSF13B) is a recently identified member of the tumor necrosis factor superfamily, expressed in monocytes, macrophages, and dendritic cells. [1] [2] [3] [4] [5] BLyS is a potent B cell co-stimulator, and promotes B cell differentiation, proliferation and survival. 1, 2, [6] [7] [8] [9] [10] In BLyS deficient mice, the number of B cells, serum IgG and IgM levels were decreased, and B cell development was blocked at the transitional T1 stage. 11 BLyS and a proliferation-inducing ligand (APRIL) bind to B cell maturation antigen (BCMA) and transmembrane activator and CAML-interactor (TACI), 4, 12, 13 which belong to the tumor necrosis factor receptor superfamily and are mainly expressed in B cells. [14] [15] [16] [17] The intracellular domains of BCMA and TACI associate with TNFreceptor-associated factors (TRAFs), leading to activation of NF-kB. 18, 19 Recently, another receptor for BLyS, BAFF-R (also called BR3) was identified, which does not bind to APRIL. 20, 21 Several lines of evidence indicate that these receptorligand systems crucially contribute to the pathogenesis of the autoimmune diseases. Transgenic mice overexpressing BLyS develop symptoms characteristic of systemic lupus erythematosus (SLE). 4, 6, 7 Circulating BLyS is elevated in SLE model mice, NZB/W F1 and MRL-lpr/ lpr. 4 In addition, TACI-Ig treatment inhibits development of proteinurea in NZB/W F1 mice, and the production of collagen-specific Abs and the progression of disease in a mouse model of rheumatoid arthritis (RA). 4, 11, 22 Recently, increase of BLyS level was also reported in the serum or synovial fluid of human SLE, RA and Sjö gren's syndrome. [23] [24] [25] Serum BLyS level was shown to be correlated with those of anti-dsDNA antibody and rheumatoid factor (RF), 24 although another study failed to show correlation with RF or with anti-Ro, anti-La with BLyS. 25 Moreover, genome-wide screening results suggested linkage of 13q32, where the gene coding for BLyS is located, with human SLE. 26 On the basis of these observations, we considered BLyS, APRIL, BCMA, TACI and BAFF-R to be strong candidates for the susceptibility gene to human autoimmune disease. In the previous study, we reported 12 variations in promoter, coding, and untranslated regions of human BCMA and demonstrated the presence of four major BCMA haplotypes in the Japanese population. 27 However, significant association of BCMA polymorphisms with SLE or RA was not detected. To date, no attempt for a systematic variation screening of human BLYS gene has been reported. In this study, we screened for variations of human BLYS, and detected variations were tested for the association with SLE and RA, in the case-control approach.
Results
Elucidation of genomic organization of human BLYS To obtain genomic DNA sequence of human BLYS, we searched for a genomic clone sequence homologous to the BLyS cDNA sequence (GenBank accession number: AF116456) by homology search program, BLAST. From the search, Homo sapiens chromosome 13 clone RPll-332J12 (accession number: AL353192) was found to contain BLYS genomic sequence. From the alignment of both sequences, exon-intron organization of human BLYS was elucidated (Figure 1 ), which was confirmed by polymerase chain reaction (PCR) and direct sequencing.
Human BLYS variation and analysis of association with SLE or RA Variation screening was carried out for the entire coding region, promoter region (up to nucleotide position À1320) and 5 0 and 3 0 untranslated regions (UTRs) of human BLYS in 10 patients with SLE, 10 patients with RA and 10 healthy individuals. The variations detected in BLYS are demonstrated in Figure 1 . The designations of the variations are based on references (28, www.dmd.nl/ mutnomen.html). The detected variation sites were examined for association using the case-control approach on 221 patients with RA, 156 patients with SLE and 227 healthy individuals.
In the coding region, one rare variation leading to an amino acid substitution within the extracellular region, Ala105Thr (c.313G4A), was detected. 105Thr allele was present in four of 221 patients with RA and in one of 156 with SLE, but in none of 227 controls. Although the difference did not reach statistical significance, the tendency for the increase of 105Thr allele carrier frequency was observed in patients with RA (P ¼ 0.058, RA vs controls, Fisher's exact test).
Four SNPs in the promoter region, À1283G4A, À87lC4T, À514T4C, and À353G4C, and one SNP in intron 1, IVSlÀ45C4G, were also detected. Genotype frequencies of each SNP are shown in Table 1 . Significant association of BLYS SNPs with susceptibility to SLE and RA was not observed. As a result of genotyping, positions À1283, À514, À353 and IVSl-45 were found to be in linkage disequilibrium. Haplotype estimation using a software for Population Genetics Data Analysis, ARLEQUIN, 29 (http://lgb.unige.ch/arlequin/) revealed three major haplotypes, which we designated as BLYS.01, 02 and 03. The estimated haplotype frequencies are shown in Table 2 .
Association of BLYS promoter SNPs with clinical and immunological characteristics of SLE We next analyzed whether BLYS SNPs are associated with any of the clinical and immunological characteristics of SLE. SLE patients were divided into subgroups according to age of onset (o20 or not), the presence or absence of lupus nephritis, central nervous system disease, serositis, hypocomplementemia, anti-Sm and dsDNA antibodies. The genotype frequencies of BLYS SNPs were compared between these subgroups. As shown in Table 3 , a tendency for increase of the À87lT/ T genotype was observed in SLE patients with anti-Sm antibody, although the difference did not reach statistical significance (P ¼ 0.082). No significant difference was observed in other characteristics (data not shown). 
Association of promoter SNPs with BLYS mRNA level in monocytes We next made an attempt to examine whether BLYS promoter SNPs were associated with BLYS mRNA level. Because BLyS is mainly expressed in monocytes, mRNA levels were compared in the monocytes isolated from peripheral blood of healthy donors carrying different BLYS promoter SNPs. The mRNA level of BLYS was analyzed by real-time semi-quantitative RT-PCR using LightCycler (Roche Diagnostics, Mannheim, Germany). As shown in Figure 2 , mRNA levels were significantly increased in individuals carrying À871T allele compared with those not carrying À871T allele (11-fold increase in average, P ¼ 0.010, Mann-Whitney U-test). Finally, we examined whether the promoter SNPs was associated with serum levels of IgG, IgA and IgM in 18 healthy individuals (À87lT/T 2, À871C/T 8, À87lC/C8). Significant difference was not detected among the three groups.
Discussion
A number of recent observations indicated that BLyS plays a pivotal role in the pathogenesis of SLE and RA. However, whether it is involved in the genetic predisposition to such diseases has not been examined. In the present study, we identified several new polymorphisms of human BLYS. Significant association of the polymorphisms with susceptibility to SLE and RA was not observed. However, the homozygotes of À871T allele were more frequently found in the patients possessing anti-Sm antibody. Of particular interest was that this promoter SNP was associated with a higher BLYS mRNA level in the monocytes. It has been reported that serum BLyS protein level is more strongly correlated with autoantibodies such as anti-DNA and rheumatoid factor than with total immunoglobulin level. 24 Our present observation may support the role for BLyS in the production of autoantibodies. In addition, a patient with SLE with severe, recurrent sialoadenitis was found to be homozygous for À871T allele (data not shown). A recent report clearly demonstrated that BLyS has a crucial role for Sjö gren's syndrome. 25 Unfortunately, only a small proportion of our patients received evaluation for Sjö gren's syndrome; therefore, statistical analysis on the association of BLYS SNP with the presence of Sjö gren's syndrome was not performed in this study.
According to the transcription factor binding prediction on the website (TFSEARCH: www.cbrc.jp/research/ db/TFSEARCH. html), position À871 corresponds to the binding site of transcription factor MZF1, which was reported to be preferentially expressed in differentiating myeloid cells. 30 Thus, it is possible that this SNP may change the binding affinity of MZF1. However, further studies are necessary to identify the transcription factor responsible for the binding to this region and to show the change in the promoter activity caused by this SNP. In addition, it would be interesting to see the association of BLyS protein level on the surface of monocytes and in sera with the promoter polymorphism; at present, such analyses cannot be done because antibodies to BLyS that can be used for flow cytometry and ELISA are not commercially available.
Within the coding region, one rare variation leading to an amino acid substitution, Ala105Thr, was detected. Although the difference did not reach statistical significance, it is interesting to note that this variation was slightly increased in the patients with RA, suggesting the possibility that this rare missense mutation may be associated with susceptibility to RA in a small proportion of patients. The four RA patients carrying this variation were positive for rheumatoid factor with variable titers, and had erosive arthritis. However, they did not exhibit a significant level of antinuclear antibodies, nor had firstdegree relatives affected with RA or SLE. However, a separate, larger-scale study will be necessary to address the association of clinical characteristics with this amino acid substitution. BLyS can be cleaved into soluble form, and both membrane-bound and soluble forms have been shown to be functional. This amino acid substitution is located between the transmembrane region and cleavage site, and remains on the surface of cells after cleavage. Therefore, if Ala105Thr is associated with any functional change, it would be more likely to be the efficiency of cleavage, rather than the binding affinity to the receptors.
There are some limitations in this study. Initial variation screening employed SSCP analysis, the sensitivity of which for the detection of new SNPs is not 100%. However, we tested at least 16 different SSCP conditions with varying temperatures with and without glycerol before concluding that SNPs are not present in the examined fragments; therefore, it is unlikely that we missed commonly present SNPs. The difference in the transcriptional activity of À871 SNP needs to be confirmed in the future using a system compatible with a larger sample size, such as serum BLyS ELISA.
Notable evidence for genetic interaction between BLYS and BCMA polymorphisms 27 was not observed (data not shown). However, such interaction should be re-evaluated after all information on the polymorphisms of the BLyS receptors (BAFF-R and TACI) becomes available. Polymorphism screening of BAFF-R and TACI is under way in our laboratory.
In conclusion, although human BLYS was found to be conserved in the coding region, several SNPs with potential functional significance were identified. One of the promoter SNPs was shown to be associated with elevated BLYS mRNA level in the monocytes, the homozygotes of which were found more frequently in SLE patients with anti-Sm antibody. These results suggested that BLYS polymorphism may be involved in the genetic susceptibility to some of the phenotypes of autoimmune diseases.
Materials and methods

Patients and healthy individuals
Variation screening of human BLYS gene was carried out in 10 patients with SLE, 10 patients with RA and 10 healthy individuals. For the detected variation sites, case-control association studies were performed on 221 patients with RA, 156 patients with SLE and 227 healthy individuals. All patients and controls were unrelated Japanese, living in Tokyo area.
The patients with RA were followed up in the Department of Allergy and Rheumatology, University of Tokyo Hospital, or Matsuta Clinic (Tokyo, Japan), consisted of 21 males and 200 females (average age 57.8 years), and fulfilled the classification criteria of American College of Rheumatology. 31 The patients with SLE were followed up in the Department of Allergy and Rheumatology, University of Tokyo Hospital, or in the Department of Rheumatology and Internal Medicine, Juntendo University Hospital, consisted of 11 males and 145 females (average age 40.0 years), and fulfilled the classification criteria of American College of Rheumatology. 32 The control group consisted of healthy laboratory workers or students, consisted of 127 males and 100 females (average age 36.6 years). Subgroups of SLE were defined by the presence or absence of clinical or immunological characteristics, according to the ACR classification criteria. 32 This study was reviewed and approved by the Research Ethics Committees of the Graduate School of Medicine, the University of Tokyo and of Juntendo University.
Genomic DNA Genomic DNA from patients and healthy individuals was purified from peripheral blood leukocytes using the QIAamp blood Kit (QIAGEN, Hilden, Germany).
Variation screening and genotyping of BLYS Variation screening and genotyping were performed using PCR-single strand conformation polymorphism (SSCP) and direct sequencing. PCR was carried out using GeneAmp reagents and AmpliTaq Gold DNA Polymerase (Perkin-Elmer, Norwalk, CT, USA). The amplification conditions consisted of initial denaturation at 941C for 10 min, followed by 35 cycles of 941C for 30 s annealing temperature for 30s and 721C for 30 s in GeneAmp PCR system 9700 (Perkin-Elmer Applied Biosystems, Foster City, CA, USA). The specific primers and annealing temperatures used in this study are listed in Table 4 . Primers were designed based on chromosome 13 clone RP11-332J12 sequence.
The SSCP analysis was performed using a minigel electrophoresis apparatus with a constant temperature control system (ATTO, Tokyo, Japan), essentially according to the method described previously. 33 The SSCP conditions are listed in Table 4 . The primer sets used for genotyping of À1283G4A, À871C4T, À514T4C, À353G4C, c.313G4A and IVS1-45C4G were Prom 1, Prom 2, Prom 4, Prom 5, Exon1-2 and Exon 2, respectively. Except for À514T4C, genotyping was performed using SSCP. No variation was detected in the fragment of Prom 3 and exon l-l, 3, 4, 5, and 6 under at least 16 different SSCP conditions.
The nucleotide sequences of the detected variations were determined by direct sequencing using ABI PRISM 310 Genetic Analyzer (Perkin-Elmer Applied Biosystems, Foster City, CA, USA). Direct sequencing was also used for genotyping of À514T4C because SSCP condition that can distinguish the two alleles was not found.
Isolation of monocytes and extraction of total RNA Peripheral blood mononuclear cells (PBMCs) were isolated from 20 ml of venous blood samples of 12 healthy individuals. After isolation of PBMCs, monocytes were isolated by positive selection using Dynabeads M-450 CD14 (Dynal, Oslo, Norway), according to the manufacturer's instructions. Briefly, PBMCs were suspended in 1 ml washing buffer (RPMI1640 containing 2% FCS). Dynabeads M-450 CD14 was added to the suspension containing PBMCs to a final concentration of 1 Â 10 7 Dynabeads M-450/ml. The suspension was incubated for 40 min on ice with gentle tilting and rotation. After incubation, the tube containing the suspension was placed in a Dynal MPC, and the supernatant was removed. Total RNA was extracted from the isolated monocytes either immediately or after the cells were stored frozen at À801C for 2-3 days, using the RNeasy Kit (QIAGEN, Hilden, Germany).
Real-time semi-quantitative RT-PCR by LightCycler
First-strand cDNA was synthesized using Oligo(dT) primer (Promega, Madison, USA) and ReverTra Ace (Toyobo, Osaka, Japan). RT-PCR was carried out using LightCycler (Roche Diagnostics, Mannheim, Germany), according to the manufacturer's instructions. One microliter of cDNA was placed into a 19 ml reaction volume containing 0.5 mM of each primer, 4 mM MgCl 2 , 2m1 LightCycler-FastStart DNA Master SYBR Green I (Roche Diagnostics, Mannheim, Germany).
The primers used for amplification of cDNA fragment of BLyS were 5 0 -GGAGAAGGCAACTCCAGTCAGAAC-3 0 (forward) and 5 0 -CAATTCATCCCCAAAGACATG-GAC-3 0 (reverse). The cycling conditions consisted of initial denaturation at 951C for 10 min, followed by 40 cycles of 951C for 5 s, 621C for 10 s, 721C for 15 s and 811C for 5 s. The fluorescent products were detected at the end of each cycle. To confirm the specificity, melting curve analysis was performed after amplification. Specific and nonspecific products are distinguishable because they have different melting temperatures depending on their nucleotide compositions. The melting temperature for the BLYS product was 84.51C. The quantification data were analyzed by fit points method using the LightCycler analysis software. In brief, the concentration of the target mRNA in each sample was estimated from the comparison of the number of cycles necessary for achieving a given fluorescence intensity within a linear range of amplification with those of serially diluted reference samples that were run at the same time. b-actin was used to normalize the total RNA levels. The primers used for amplification of cDNA fragment of b-actin were 5 0 -TCCTGTGGCATCCAC-GAAACT-3 0 (forward) and 5 0 -GAAGCATTTGCGGTG-GACGAT-3 0 (reverse).
Statistical analysis
The frequencies of the genotypes were compared using the w 2 test. When one or more of the variables in the 2 Â 2 contingency tables was 5 or less, Fisher's exact test was employed. Haplotype estimation was performed using ARLEQUIN software. 29 The mRNA levels of BLYS for healthy individuals with and without À871T were compared using the Mann-Whitney U-test. Association of serum IgG, IgA and IgM levels with the genotype was analyzed using ANOVA. P-values o0.05 were regarded as statistically significant. All statistical analyses were done using StatView J5.0 (SAS Institute Inc, Cary, NC).
